Phathom Pharmaceuticals, Inc. Operating Income Loss

• Phathom Pharmaceuticals, Inc. showed an increase of +42.3% in Operating Income Loss from 2024 to 2025.
• This data is from Phathom Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2018 to 2025), Phathom Pharmaceuticals, Inc.'s Operating Income Loss has declined by 12,960.1%.
• Historical annual values: Fiscal year 2025: -$159.99 million | Fiscal year 2024: -$277.47 million | Fiscal year 2023: -$167.31 million | Fiscal year 2022: -$172.44 million | Fiscal year 2021: -$135.08 million | Fiscal year 2020: -$125.67 million | Fiscal year 2019: -$106.22 million | Fiscal year 2018: -$1.23 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026